Treatment of Progressive Myoclonic Epilepsy in Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease)
Progressive myoclonic epilepsy arising in the context of neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a clinically distinct presentation that calls for a disease-specific therapeutic strategy rather than generic seizure management.
Clinical scenario: This protocol applies to patients with progressive myoclonic epilepsy in the setting of neuronal ceroid lipofuscinosis type 2 (CLN2 disease) — one of the most prevalent forms of neuronal ceroid lipofuscinosis.
Treatment Approach
An approved enzyme-replacement therapy targeting the underlying enzymatic deficiency in CLN2 disease is the cornerstone of management in this setting. Full eligibility criteria, administration pathway, and monitoring parameters are detailed in the complete protocol.
References
- One of the most prevalent types of NCL is type 2 (CLN2) disease.
- Cerliponase alfa (Brineura) is an intracerebroventricular enzyme-replacement therapy that was approved for the treatment of CLN2 in 2017.
- In clinical trials, cerliponase alfa, administered via a surgically implanted intraventricular access device, slowed the loss of ambulation.
- Cerliponase alfa is approved in the USA for children aged ≥ 3 years and in the EU for all age groups.
View source ↗